Cargando…

Thioridazine combined with carboplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells

Cancer stem cells (CSCs) in triple-negative breast cancer (TNBC) are closely related to tumorigenesis and metastasis. Thioridazine (THZ) is a usual phenothiazine antipsychotic drug that can destroy CSCs. We aimed to explore whether THZ could sensitize metastatic TNBC cells, especially the CSCs, to c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yi, Xia, Leiming, Lin, Jing, Gong, Li, Xia, Yang, Xu, Yang, Liu, Liu, Bao, Jian, Zhang, Congshu, Chai, Yuqing, Li, Hongxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530598/ https://www.ncbi.nlm.nih.gov/pubmed/36191461 http://dx.doi.org/10.1016/j.tranon.2022.101549

Ejemplares similares

Thioridazine Sensitizes Esophageal Carcinoma Cell Lines to Radiotherapy-Induced Apoptosis In Vitro and In Vivo
por: Li, Hongxia, et al.
Publicado: (2016)

Targeting Lung Cancer Stem Cells with Antipsychological Drug Thioridazine
por: Yue, Haiying, et al.
Publicado: (2016)

Thioridazine enhances sensitivity to carboplatin in human head and neck cancer cells through downregulation of c-FLIP and Mcl-1 expression
por: Seo, Seung Un, et al.
Publicado: (2017)

Thioridazine has potent antitumor effects on lung cancer stem-like cells
por: Shen, Jiani, et al.
Publicado: (2017)

Effect of Thioridazine on Erythrocytes
por: Lang, Elisabeth, et al.
Publicado: (2013)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Combining thioridazine and loratadine for the treatment of gastrointestinal tumor
por: Chen, Tingting, et al.
Publicado: (2017)

Codelivery of thioridazine and doxorubicin using nanoparticles for effective breast cancer therapy
por: Jin, Xun, et al.
Publicado: (2016)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
por: Moens, Stijn, et al.
Publicado: (2021)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
por: Singh, Jasmeet Chadha, et al.
Publicado: (2014)

Repurposing Thioridazine (TDZ) as an anti-inflammatory agent
por: Baig, Mirza S., et al.
Publicado: (2018)

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
por: Yong, Min, et al.
Publicado: (2020)

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy
por: Yong, Min, et al.
Publicado: (2020)

Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer: A meta-analysis of randomized controlled trials
por: Wang, Li-Yang, et al.
Publicado: (2017)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
por: Wu, Rongrong, et al.
Publicado: (2021)

Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis
por: Lu, Meiling, et al.
Publicado: (2015)

A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer
por: Ou, Junwen, et al.
Publicado: (2020)

The Effect of Fluphenazine and Thioridazine on Toxoplasma gondii In Vivo
por: SARAEI, Mehrzad, et al.
Publicado: (2016)

Molecular mechanisms of thioridazine resistance in Staphylococcus aureus
por: Wassmann, Claes Søndergaard, et al.
Publicado: (2018)

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases
por: Deshpande, Devyani, et al.
Publicado: (2016)

Autophagy in Osteosarcoma Cancer Stem Cells Is a Critical Process which Can Be Targeted by the Antipsychotic Drug Thioridazine
por: Camuzard, Olivier, et al.
Publicado: (2020)

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
por: Vetter, Marcus, et al.
Publicado: (2017)

Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer
por: Abreu de Oliveira, Willy Antoni, et al.
Publicado: (2021)

Selective Effects of Thioridazine on Self-Renewal of Basal-Like Breast Cancer Cells
por: Tegowski, Matthew, et al.
Publicado: (2019)

Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis
por: Jin, Guixiu, et al.
Publicado: (2013)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Thioridazine Enhances Cisplatin-Induced DNA Damage in Cisplatin-Resistant Human Lung Cancer Cells
por: Luo, Yuanyuan, et al.
Publicado: (2022)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Effect of thioridazine on antioxidant status of HEMn-DP melanocytes
por: Otręba, Michał, et al.
Publicado: (2015)

Anti-staphylococcal activity and mode of action of thioridazine photoproducts
por: Tozar, Tatiana, et al.
Publicado: (2020)

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
por: Sipos, O., et al.
Publicado: (2021)

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2023)

Triple-synergistic MOF-nanozyme for efficient antibacterial treatment
por: Wang, Muxue, et al.
Publicado: (2022)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t8euktuuqng8lntg2t991o68ic